StockData

Accendra Health vs AdaptHealth

ACH and AHCO side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACH and AHCO compare

AdaptHealth is the larger company, worth 105 times as much as Accendra Health ($1.1B against $10.0M).

AdaptHealth grew revenue faster over the last twelve months (4.2% versus −7.1% for Accendra Health).

Accendra Health keeps more of each dollar of sales as profit, with a net margin of −6.7% compared with −7.1% at AdaptHealth.

AdaptHealth scores higher on the StockData Score (6 against 5 for Accendra Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACHAHCO
Size and price
Market cap$10.0M$1.1B
Share price$0.130$7.73
Change, 1 year−95.6%−17.1%
Change, 5 years−99.7%−64.2%
Beta (5Y)–−1.50
Employees6,50011K
StockData Score
Total score56 (better)
Valuation score4 (better)3
Growth score00
Performance score1 (better)0
Health score03 (better)
Dividend score00
Valuation
P/S0.0× (better)0.3×
P/B–0.8×
EV/EBITDA7.4× (better)10.6×
P/FCF–10.8×
FCF yield−1992%9.3% (better)
Fair value$8.62$13.53
Margin of safety98.5% (better)42.9%
Growth
Revenue growth (TTM)−7.1%4.2% (better)
Revenue growth, 5Y average−20.1%25.2% (better)
Net income growth (TTM)–−383%
EPS growth (TTM)–−419%
Profitability
Gross margin44.1% (better)17.0%
Operating margin0.17% (better)−4.5%
Net margin−6.7% (better)−7.1%
FCF margin−7.8%3.0% (better)
Return on equity–−15.4%
Return on invested capital0.24% (better)−3.4%
Financial health
Debt / equity–1.37
Net debt / EBITDA7.356.79 (better)
Interest coverage0.0×–
Current ratio0.411.12 (better)
Altman Z-score0.200.62 (better)
Piotroski F-score24 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions81.1%104%
Held by insiders21.4%14.7%
Insider net buying, 12 months–$49.1M
Short interest, % of float16.8%9.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.